Approval · Notice of Compliance 514 · 2003
ESTRADERM: Notice of Compliance 514
Issued December 30, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 514
- Date
- December 30, 2003
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update resulting from the women's health initiative (whi) study
- Therapeutic class
- Estrogen
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ESTRADERM | Not yet assigned | — |